Monday, November 16, 2026

Boryung, Celltrion Pharm to Jointly Sell Six Diabetes Drugs... Expand Market Push

Input
2026-11-16 18:15:33
Updated
2026-11-16 18:15:33
At the signing ceremony for a joint promotion and exclusive sales and distribution agreement for Nesina and Actos, held at Celltrion Pharm’s Gwacheon office on the 16th, Jung Woong-je, head of sales at Boryung Co. (left), and Celltrion Pharm CEO Yoo Young-ho pose for a commemorative photo. Courtesy of Boryung
[Financial News] Boryung and Celltrion Pharm are set to jointly sell diabetes treatments. Boryung, which has been expanding its existing diabetes treatment business, will broaden its sales foothold in the diabetes treatment market after securing six additional originator drugs.
Boryung and Celltrion Pharm said on the 16th that they had signed an agreement to jointly sell the Nesina and Actos product lines for Type 2 diabetes in South Korea.
The two companies will jointly handle sales and marketing for six products starting next January: Nesina Tablets, Nesina Met Tablets, Nesina Met Extended-Release Tablets, Actos Tablets, Actos Met Tablets and Nesina Act Tablets.
Nesina is an originator drug containing alogliptin, a DPP-4 inhibitor, while Actos is a treatment containing pioglitazone, a TZD that improves insulin resistance. With combination drugs such as Nesina Act, which combines the two ingredients, the product range offers prescription options tailored to patients’ conditions and stages of treatment.
The product lines were acquired by Celltrion from the multinational pharmaceutical company Takeda in 2020. According to UBIST, a pharmaceutical market research firm, prescription sales totaled 51.7 billion won last year, giving the products a sizable prescription base in South Korea’s diabetes treatment market.
The agreement is also expected to support Boryung’s expansion in the diabetes business. Boryung has been broadening its diabetes treatment portfolio with Trudapa, which contains dapagliflozin, and Truebirdy, a combination of dapagliflozin and pioglitazone. Adding originator products in the DPP-4 inhibitor and TZD classes will further diversify its treatment lineup.
In particular, Boryung plans to focus its diabetes treatment sales capabilities through Boryung Pharma Solution, a sales and marketing subsidiary scheduled to launch next January. Its strategy is to combine the two companies’ sales networks and product competitiveness to raise product awareness among healthcare providers and expand the prescription market.

[email protected] Jung Sang-hee Reporter